Related Experiment Videos
Hemoglobin-based oxygen carrier preserves submaximal exercise capacity in humans
G S Hughes1, E P Yancey, R Albrecht
1Upjohn Company, Kalamazoo, MI 49001, USA.
Clinical Pharmacology and Therapeutics
|October 1, 1995
Summary
This study found that hemoglobin-based oxygen carrier (HBOC-201) provided similar exercise capacity to autologous transfusion but with improved oxygen uptake and lower lactate levels. HBOC-201 offers a viable alternative for oxygen delivery.
Area of Science:
- Biomedical Engineering
- Pharmacology
- Physiology
Background:
- Hemoglobin-based oxygen carriers (HBOCs) are investigated as blood substitutes.
- Understanding the pharmacodynamics and pharmacokinetics of HBOCs is crucial for clinical application.
- Polymerized bovine hemoglobin (HBOC-201) is a novel HBOC.
Purpose of the Study:
- To evaluate exercise capacity following autologous transfusion versus HBOC-201.
- To define the pharmacodynamics and pharmacokinetics of HBOC-201.
- To compare the physiological effects of HBOC-201 and autologous transfusion.
Main Methods:
- Randomized, single-blind, two-way crossover study in 6 healthy males.
- Involved phlebotomy, isovolemic hemodilution with Ringer's lactate, and either autologous transfusion or HBOC-201 infusion.
- Bicycle exercise stress tests were performed before and after interventions.
Main Results:
- Similar exercise and diffusion capacity between HBOC-201 and autologous transfusion.
- Lower lactate levels for up to 24 hours during HBOC-201 infusion.
- Increased resting oxygen uptake and carbon dioxide production with HBOC-201; HBOC-201 half-life was approximately 23 hours.
Conclusions:
- HBOC-201 demonstrated comparable exercise and diffusion capacity to autologous transfusion.
- HBOC-201 led to enhanced oxygen uptake, carbon dioxide production, and reduced lactate levels.
- Physiologically, 1 gm of bovine hemoglobin in HBOC-201 was equivalent to 3 gm of human hemoglobin from autologous transfusion.